Albumin/interferon alpha 2A fusion protein

Drug Profile

Albumin/interferon alpha 2A fusion protein

Alternative Names: Recombinant human serum albumin/interferon alpha2a fusion protein

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Bio-Fortune
  • Class Albumins; Antivirals; Interferons; Recombinant fusion proteins
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Feb 2016 No recent reports on development identified - Phase-I/II for Hepatitis B in China (SC)
  • 01 Nov 2014 Beijing Bio-Fortune completes a phase I/II trial in Hepatitis B in China (NCT01997944)
  • 25 Nov 2013 Phase-I/II clinical trials in Hepatitis B in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top